Teva outlines higher 2026 revenue midpoint by $75M while targeting AUSTEDO $2.45B-$2.6B and AJOVY $850M-$870M (NYSE:TEVA)
· seekingalpha.com
Teva (TEVA) Q2 2026 earnings call recap: raised revenue guidance on AUSTEDO/AJOVY/UZEDY, Emalex IPR&D hit, IRA & inventory risks—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...